ARC
ENTA icon

Absolute Return Capital’s Enanta Pharmaceuticals ENTA Stock Holding History

Absolute Return Capital’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-3,932
Closed -$169K – 711
2014
Q2 		$169K Sell
3,932
-7,883
-67% -$301K ﹤0.01% 1042
2014
Q1 		$472K Buy
+11,815
New +$429K 0.01% 864

Other funds holding ENTA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
SAM
Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GC
Guggenheim Capital Chicago, Illinois $12.9B AUM 27.3% 1-Year Est. Return

Absolute Return Capital's ENTA Position: Q3 2014 in Review

Absolute Return Capital sold out of Enanta Pharmaceuticals (ENTA) in Q3 2014, closing a stake of 3,932 shares — an estimated $169K sold.

Absolute Return Capital first reported a position in ENTA in Q1 2014 and held it in 2 quarters. The position peaked at $472K in Q1 2014. 111 funds tracked by Wall St. Rank hold ENTA as of Q3 2014.

  • Absolute Return Capital reported no remaining Enanta Pharmaceuticals position as of Q3 2014 after selling out during the quarter.
  • Absolute Return Capital sold 3,932 Enanta Pharmaceuticals shares in Q3 2014, an estimated $169K.
  • Absolute Return Capital first reported a position in Enanta Pharmaceuticals in Q1 2014 and held it in 2 quarters.
  • Absolute Return Capital's Enanta Pharmaceuticals position peaked at $472K in Q1 2014.
  • 111 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q3 2014.

Based on Absolute Return Capital's 13F filing for Q3 2014, filed 14 Nov 2014.